References
1. Chuu, CP, Hiipakka, RA, Fukuchi, J, Kokontis, JM, and Liao, S. 2005.
Androgen causes growth suppression and reversion of androgen-independent
prostate cancer xenografts to an androgen-stimulated phenotype in
athymic mice. Cancer Res 65(6): 2082-2084.
2. Denmeade, SR and Isaacs, JT. 2010. Bipolar androgen therapy: the
rationale for rapid cycling of supraphysiologic androgen/ablation in men
with castration resistant prostate cancer. Prostate 70(14): 1600-1607.
3. Denmeade, SR, Wang, H, Agarwal, N, et al. 2021. TRANSFORMER: A
Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus
Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic
Prostate Cancer. Journal of Clinical Oncology 39(12): 1371-1382.
4. Markowski, MC, Wang, H, Sullivan, R, et al. 2020. A Multicohort
Open-label Phase II Trial of Bipolar Androgen Therapy in Men with
Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison
of Post-abiraterone Versus Post-enzalutamide Cohorts. Eur Urol 79(5):
692-699.
5. Mohammad, OS, Nyquist, MD, Schweizer, MT, et al. 2017.
Supraphysiologic Testosterone Therapy in the Treatment of Prostate
Cancer: Models, Mechanisms and Questions. Cancers 9(12): 166.
6. Mori, K, Kimura, T, Ito, K, et al. 2018. Earlier use of androgen
receptor-axis-targeted drugs may improve overall survival in patients
with non-metastatic castration-resistant prostate cancer. Prostate
78(10): 766-772.
7. Moses, M, Koksal, U, Ledet, E, et al. 2020. Evaluation of the genomic
alterations in the androgen receptor gene during treatment with
high-dose testosterone for metastatic castrate-resistant prostate
cancer. Oncotarget 11(1): 15-21.
8. Song, W, Soni, V, Soni, S, and Khera, M. 2017. Testosterone inhibits
the growth of prostate cancer xenografts in nude mice. BMC Cancer 17(1):
635.
9. Tannock IF, dWR, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S,
Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. 2004.
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced
prostate cancer. N Engl J Med 351(15): 1502-1512.
10. Teply, BA, Wang, H, Luber, B, et al. 2017. Bipolar androgen therapy
in men with metastatic castration-resistant prostate cancer after
progression on enzalutamide: an open-label, phase 2, multicohort study.
Lancet Oncol 19(1): 76-86.
11. Yu P, DX, Cheng Y, Liu C, Chen Y, Liu W, Yin B, Wang X,Tao Z. 2017.
Androgen-independent LNCaP cells are a subline of LNCaP cells with a
more aggressive phenotype and androgen suppresses their growth by
inducing cell cycle arrest at the G1 phase. Int J Mol Med 40:1426-1434.